StreetAlpha.app
Home › Stocks › CLDX

Celldex Therapeutics, Inc. (CLDX)

Healthcare
$27.42
▼ −1.93%
LAST CLOSE · NOV 20

Celldex develops antibody drugs for mast cell driven and other inflammatory, allergic and autoimmune diseases. It last closed at $27.42 on Nov 20, down 1.93% on the day. The next earnings report for CLDX is expected around Wed, Feb 24, 2027, after the close. For the quarter ended Sep 2026, CLDX reported EPS of -$0.96 on revenue of $0. Over its last 8 reports the stock moved an average of 3.3% the session after earnings. Over the last 12 months CLDX insiders bought $0 of stock on the open market and sold $121K, according to SEC Form 4 filings.

AI Auto Pilots
Is CLDX in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold CLDX.

Key Stats

Last 12 months
Results
Revenue
$158K
−93.9% vs a year ago
Net income
−$309.1M
−195608.9% margin
EPS (diluted)
−$4.29
Free cash flow
−$259.7M
−164391.8% margin
Valuation
Market cap
$2.2B
78.5M shares
P/E
–
No P/E while losing money
Price to sales
13631.0
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$27.0M
At Sep 30
Shareholder equity
$649.5M
Shares outstanding
78.5M
At Oct 28
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $4.7M$4.7MFY2021FY2022: $2.4M$2.4MFY2022FY2023: $6.9M$6.9MFY2023FY2024: $7.0M$7.0MFY2024FY2025: $1.5M$1.5MFY2025

From CLDX's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.

Next report
Feb 24
Estimated date · After the close
Reported EPS
-$0.96
Quarter ended Sep 2026
Year ago EPS
-$1.01
Same quarter last year
Revenue
$0
Last reported quarter
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$0.71Dec '24Mar 2025: -$0.81Mar '25Jun 2025: -$0.85Jun '25Sep 2025: -$1.01Sep '25Dec 2025: -$1.23Dec '25Mar 2026: -$1.18Mar '26Jun 2026: -$0.94Jun '26Sep 2026: -$0.96Sep '26Latest -$0.96
Revenue by quarter
Dec 2024: $1.2MDec '24Mar 2025: $695,000Mar '25Jun 2025: $730,000Jun '25Sep 2025: $0Sep '25Dec 2025: $121,000Dec '25Mar 2026: $15,000Mar '26Jun 2026: $22,000Jun '26Sep 2026: $0Sep '26Latest $0
How CLDX moved after its last 8 reports
Average move the session after a report ±3.3%
Nov 5, 2026After the close+5.7%
Aug 6, 2026After the close+0.4%
May 7, 2026After the close+1.9%
Feb 25, 2026After the close−0.6%
Nov 10, 2025After the close+7.5%
Aug 7, 2025After the close−2.6%
May 8, 2025After the close−6.1%
Feb 27, 2025After the close+1.3%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on CLDXStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
Analyst calls from around the web
Last 90 days on CLDX: 0 upgrades, 0 downgrades, 0 initiations · Targets mentioned $50.00 to $58.00
BarclaysTarget cut
Nov 22  
HC WainwrightNew target
Nov 21 $58.00
BarclaysTarget cut
Nov 21 $50.00
BarclaysTarget cut
Nov 20 $50.00
HC WainwrightTarget cut
Nov 20  

StreetAlpha's curated list of analyst calls collected from around the web. It may be incomplete or inaccurate, is not a consensus and is not advice.

AI Starter and AI Pro
Full analyst coverage on CLDX
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on CLDX

Technical Analysis

CLDX · as of the Nov 20 close · updated each morning
Downtrend

The stock is 7% below its 20 day and 13% below its 50 day average. It is 20% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 39). The nearest support is the Pivot S1 at $26.57, and the nearest resistance the Pivot at $27.50.

Short trendBearish
Long trendBearish
MomentumWeak
StretchNormal
VolatilityHigh, 5.3%/day
Key levels
$45.1452 week high+64.6%
$35.03100 day average+27.8%
$32.93200 day average+20.1%
$30.9250 day average+12.8%
$30.39Swing high (Oct 27)+10.8%
$29.2520 day average+6.7%
$28.35Pivot R1+3.4%
$27.50Pivot+0.3%
$27.42Last close
$26.57Pivot S1−3.1%
$22.3352 week low−18.6%
Indicators
RSI (14)38.72Weak, oversold below 30Neutral
MACD-0.84Below its signal lineBearish
Stochastic11.8Near the bottom of its rangeOversold
ADX (14)21.2Weak trend
Williams %R-84.6Oversold below −80, overbought above −20Oversold
CCI (20)-157.1Oversold below −100, overbought above 100Oversold
Rate of change−8.2%Change over 10 sessionsBearish
ATR (14)$1.46Typical daily range, 5.3% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for CLDX

What happened before

See how CLDX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow CLDX usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How CLDX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2005.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for CLDXHow many large options trades hit CLDX, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

CLDX Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ▲129 buying vs 106 selling
  • ▲Held by funds +6.1 pts
  • ▼Funds holding -6
  • ▼Superinvestors: 1 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding249255−2.4%
In funds' top 10711−36.4%
Held by funds115.3%109.2%+6.1 pts
New / increased36 / 9345 / 106−14.6%
Reduced / sold out64 / 4257 / 21+35.9%
Put/call ratio0.866.02−85.7%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See CLDX institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

CLDX Insider Trading

All filings →
Insider trading · 12 months
Insiders are only selling
Bought$00 buys · 0 insiders
Sold$121K1 sale · 1 insider
2025-12 sold $121KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Dec 4, 2025Freddy A. JimenezSVP & General CounselSale4,166$29.10$121K
Nov 13, 2025Richard M. WrightInsiderSale49,298$24.00$1.2M
Aug 13, 2025Freddy A. JimenezSVP & General CounselSale771$24.77$19K
Nov 11, 2024Anthony S MarucciPresident & CEOBuy11,500$26.82$308K
Every insider buy and sale for CLDX over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See CLDX insider trades →

From SEC Form 4 filings by CLDX's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether CLDX is in one of them and how their past CLDX trades turned out.

CLDX in the AI portfolios
Loading…

CLDX News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered CLDX in an article yet. Here's the latest on the wider market.

CLDX in the news

About Celldex Therapeutics

Celldex is a biopharmaceutical company based in Hampton, New Jersey. It develops antibody drugs aimed at diseases driven by mast cells, including chronic urticaria, prurigo nodularis and atopic dermatitis, as well as other severe inflammatory, allergic and autoimmune conditions. Its main candidates are barzolvolimab, a monoclonal antibody, and a bispecific antibody platform for new inflammatory targets. The company has not yet sold any drugs commercially and is focused on patients whose current treatment options are inadequate.

Headquarters
Hampton, NJ